| SKU | Size | Availability | Price | Qty |
|---|---|---|---|---|
| I656576-1ml | 1ml | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $770.90 |
| Specifications & Purity | 10mM in DMSO |
|---|---|
| Storage Temp | Desiccated,Store at -80°C |
| Shipped In | Ice chest + Ice pads |
| Product Description | INT-767 is a dual farnesoid X receptor (FXR)/TGR5 agonist with mean EC 50 s of 30 and 630 nM, respectively. In Vitro INT-767 does not show cytotoxic effects in HepG2 cells, does not inhibit cytochrome P450 enzymes, is highly stable to phase I and II enzymatic modifications, and does not inhibit the human ether-a-go-go -related gene potassium channel. MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo INT-767 (10-20 mg/kg; i.p.; daily for 2 weeks) decreases plasma total cholesterol and triglyceride levels in db/m and db/db mice. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Male 8-week old C57BKS/J db/db mice, control nondiabetic db/m miceDosage: 10, 20 mg/kg Administration: Intraperitoneal injection; daily for 2 weeks Result: Decreased plasma total cholesterol and triglyceride levels. |
| Canonical SMILES | CCC1C2CC(CCC2(C3CCC4(C(C3C1O)CCC4C(C)CCOS(=O)(=O)[O-])C)C)O.[Na+] |
|---|---|
| Molecular Weight | 494.66 |
Enter Lot Number to search for COA:
